Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia

We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven pati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Jabbour, Elias, Garcia-Manero, Guillermo, Cortes, Jorge, Ravandi, Farhad, Plunkett, William, Gandhi, Varsha, Faderl, Stefan, O’Brien, Susan, Borthakur, Gautam, Kadia, Tapan, Burger, Jan, Konopleva, Marina, Brandt, Mark, Huang, Xuelin, Kantarjian, Hagop
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3859239/
https://ncbi.nlm.nih.gov/pubmed/22534616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.03.003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak